

Bruno Ledergerber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689071/publications.pdf>

Version: 2024-02-01

221
papers

21,769
citations

13865

67
h-index

9345

143
g-index

225
all docs

225
docs citations

225
times ranked

15852
citing authors

#	ARTICLE	IF	CITATIONS
1	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.	4.0	3
2	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2194-e2202.	5.8	47
3	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. <i>Clinical Infectious Diseases</i> , 2021, 73, e2070-e2076.	5.8	7
4	Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endo graft infections. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab041.	2.1	2
5	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021, 11, 4586.	3.3	8
6	PET/CT in therapy control of infective native aortic aneurysms. <i>Scientific Reports</i> , 2021, 11, 5065.	3.3	9
7	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	3.9	66
8	Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	2
9	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.	5.8	5
10	Impact of unknown incidental findings in PET/CT examinations of patients with proven or suspected vascular graft or endo graft infections. <i>Scientific Reports</i> , 2021, 11, 13747.	3.3	6
11	PET/CT helps to determine treatment duration in patients with resected as well as inoperable alveolar echinococcosis. <i>Parasitology International</i> , 2021, 83, 102356.	1.3	12
12	Editor's Choice - Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endo graft Infection: Results from the Prospective Vascular Graft Cohort Study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 62, 251-257.	1.5	22
13	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.	2.2	6
14	Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endo graft Infection: Results from the Prospective Vascular Graft Cohort Study. <i>Journal of Vascular Surgery</i> , 2021, 74, 1046.	1.1	0
15	A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12532.	2.6	3
16	Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa438.	0.9	4
17	Rapid Progression of Kidney Dysfunction in People Living With HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores. <i>Journal of Infectious Diseases</i> , 2020, 223, 2145-2153.	4.0	7
18	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	4.0	22

#	ARTICLE	IF	CITATIONS
19	Diagnostic Accuracy of PET/CT and Contrast Enhanced CT in Patients With Suspected Infected Aortic Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 59, 972-981.	1.5	26
20	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 135-138.	3.0	7
21	Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 884-889.	5.8	11
22	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2019, 70, 890-897.	5.8	7
23	Inadequate Perioperative Prophylaxis and Postsurgical Complications After Graft Implantation Are Important Risk Factors for Subsequent Vascular Graft Infections: Prospective Results From the Vascular Graft Infection Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 621-630.	5.8	23
24	Comparing diagnostic accuracy of 18F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1359-1368.	6.4	28
25	Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , 2018, 67, 708-716.	5.8	34
26	Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. <i>European Heart Journal</i> , 2018, 39, 2147-2154.	2.2	47
27	Estimating the treatment effect on the treated under time-dependent confounding in an application to the Swiss HIV Cohort Study. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2018, 67, 103-125.	1.0	2
28	Perioperative Antibiotic Prophylaxis Has No Effect on Time to Positivity and Proportion of Positive Samples: a Cohort Study of 64 <i>Cutibacterium acnes</i> Bone and Joint Infections. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	11
29	IF11. Good Early Results of Negative Pressure Wound Nonexcisional Treatment for Prosthetic Graft Infection Are Durable: It Is a Game Changer. <i>Journal of Vascular Surgery</i> , 2018, 67, e62.	1.1	0
30	The role of FDG PET/CT in therapy control of aortic graft infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1987-1997.	6.4	32
31	Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw809.	5.8	34
32	Dynamic Models for Estimating the Effect of HAART on CD4 in Observational Studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. <i>Biometrics</i> , 2017, 73, 294-304.	1.4	8
33	Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. <i>BMJ Open</i> , 2017, 7, e014679.	1.9	9
34	Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx177.	0.9	10
35	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.	0.9	20
36	A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw089.	0.9	16

#	ARTICLE	IF	CITATIONS
37	Optimal Length of Cultivation Time for Isolation of <i>Propionibacterium acnes</i> in Suspected Bone and Joint Infections Is More than 7 Days. <i>Journal of Clinical Microbiology</i> , 2016, 54, 3043-3049.	3.9	90
38	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016, 95, e5094.	1.0	22
39	Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape. <i>Infection</i> , 2016, 44, 521-529.	4.7	7
40	Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw101.	0.9	5
41	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.9	38
42	The HIV care cascade in Switzerland. <i>Aids</i> , 2015, 29, 2509-2515.	2.2	72
43	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.	3.0	52
44	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.	2.5	18
45	Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). <i>PLoS ONE</i> , 2015, 10, e0140943.	2.5	40
46	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.	4.0	61
47	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. <i>Journal of Hepatology</i> , 2015, 63, 573-580.	3.7	46
48	Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 4.	1.7	15
49	Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. <i>Aids</i> , 2015, 29, 231-238.	2.2	30
50	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv257.	3.0	6
51	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0133879.	2.5	5
52	Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0142923.	2.5	32
53	Role of MicroRNA Modulation in the Interferon- α /Ribavirin Suppression of HIV-1 In Vivo. <i>PLoS ONE</i> , 2014, 9, e109220.	2.5	7
54	Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19667.	3.0	8

#	ARTICLE	IF	CITATIONS
55	Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014. <i>Journal of the International AIDS Society</i> , 2014, 17, 19768.	3.0	11
56	Antibiotic susceptibility of <i>Clostridium difficile</i> is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. <i>BMC Infectious Diseases</i> , 2014, 14, 607.	2.9	29
57	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu040.	0.9	61
58	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E318-E329.	2.4	16
59	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	5.8	75
60	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.	1.9	36
61	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>in Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 763-767.	3.4	29
62	Accounting for baseline differences and measurement error in the analysis of change over time. <i>Statistics in Medicine</i> , 2014, 33, 2-16.	1.6	4
63	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.	4.0	16
64	Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2363-2368.	3.2	34
65	Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus. <i>Clinical Infectious Diseases</i> , 2014, 59, 1386-1393.	5.8	9
66	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , 2013, 27, 907-918.	2.2	12
67	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7
68	Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 870-879.	5.8	42
69	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 28-35.	2.1	86
70	Response to Calcagno Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, e14-e15.	2.1	1
71	Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. <i>PLoS ONE</i> , 2013, 8, e74024.	2.5	12
72	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	1.9	34

#	ARTICLE	IF	CITATIONS
73	Role of retroviral restriction factors in the interferon- λ -mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3035-3040.	7.1	129
74	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. Archives of Internal Medicine, 2012, 172, 1313.	3.8	31
75	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.	5.8	32
76	Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. Aids, 2012, 26, 193-205.	2.2	78
77	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. Aids, 2012, 26, 315-323.	2.2	35
78	Effect of Hepatitis C Treatment on Cd4 ⁺ T-C El L Counts And The Risk Of Death In HIV-HCV-Coinfected Patients: The Cohere Collaboration. Antiviral Therapy, 2012, 17, 1541-1550.	1.0	7
79	Polymorphic Mutations Associated With the Emergence of the Multinucleoside/Tide Resistance Mutations 69 Insertion and Q151M. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 105-112.	2.1	9
80	Effect of Acetazolamide and AutoCPAP Therapy on Breathing Disturbances Among Patients With Obstructive Sleep Apnea Syndrome Who Travel to Altitude. JAMA - Journal of the American Medical Association, 2012, 308, 2390.	7.4	84
81	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	9.1	41
82	Predictive Cross-validation for the Choice of Linear Mixed-Effects Models with Application to Data from the Swiss HIV Cohort Study. Biometrics, 2012, 68, 53-61.	1.4	8
83	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. PLoS ONE, 2012, 7, e37983.	2.5	15
84	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. PLoS ONE, 2012, 7, e44454.	2.5	456
85	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PLoS ONE, 2012, 7, e50307.	2.5	16
86	Causality, Mediation and Time: A Dynamic Viewpoint. Journal of the Royal Statistical Society Series A: Statistics in Society, 2012, 175, 831-861.	1.1	70
87	Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. AIDS and Behavior, 2012, 16, 245-255.	2.7	20
88	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	2.1	13
89	Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 36-43.	2.1	142
90	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 24-31.	2.1	23

#	ARTICLE	IF	CITATIONS
91	A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. <i>HIV Clinical Trials</i> , 2011, 12, 109-117.	2.0	29
92	Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2011, 30, 2947-2958.	1.6	12
93	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipotrophy. <i>Journal of Infectious Diseases</i> , 2011, 203, 620-624.	4.0	11
94	Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 791-797.	4.0	9
95	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.	4.0	74
96	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , 2011, 60, 1506-1519.	12.1	60
97	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2011, 53, 1130-1139.	5.8	525
98	Noncirrhotic Portal Hypertension and Didanosine: A Re-Analysis. <i>Clinical Infectious Diseases</i> , 2011, 52, 154-155.	5.8	17
99	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.	5.8	53
100	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.	4.0	89
101	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	5.8	127
102	Estimating Loss to Follow-Up in HIV-Infected Patients on Antiretroviral Therapy: The Effect of the Competing Risk of Death in Zambia and Switzerland. <i>PLoS ONE</i> , 2011, 6, e27919.	2.5	54
103	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
104	High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naïve and successfully treated Swiss HIV patients. <i>Aids</i> , 2010, 24, 1127-1134.	2.2	159
105	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 413-423.	1.0	172
106	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570.	1.0	12
107	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.	1.0	35
108	Treatment Modification in Human Immunodeficiency Virus-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010, 170, 57.	3.8	127

#	ARTICLE	IF	CITATIONS
109	A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2010, 29, 2757-2768.	1.6	61
110	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 217-230.	1.5	104
111	Different Patterns of Inappropriate Antimicrobial Use in Surgical and Medical Units at a Tertiary Care Hospital in Switzerland: A Prevalence Survey. <i>PLoS ONE</i> , 2010, 5, e14011.	2.5	85
112	Frequency and Determinants of Unprotected Sex among HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 1314-1322.	5.8	83
113	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New-Onset Diabetes Mellitus in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2010, 51, 1090-1098.	5.8	26
114	Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase. <i>Journal of Infectious Diseases</i> , 2010, 201, 1054-1062.	4.0	27
115	Reply to Chang and Garcia-Pagan. <i>Clinical Infectious Diseases</i> , 2010, 50, 128-129.	5.8	3
116	Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	4.0	172
117	HIV-1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 51, 620-628.	5.8	26
118	Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-Infection. <i>Clinical Infectious Diseases</i> , 2010, 50, 502-511.	5.8	88
119	Cohort Profile: The Swiss HIV Cohort Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1179-1189.	1.9	322
120	Reply to Kuniholm et al. <i>Clinical Infectious Diseases</i> , 2010, 50, 1546-1547.	5.8	0
121	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678.	2.2	353
122	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 464-471.	2.1	17
123	Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 262-270.	2.1	243
124	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per $\hat{1}/4$ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	18.7	82
125	Risk factors for urinary tract infections due to ciprofloxacin-resistant <i>Escherichia coli</i> in a tertiary care urology department in Switzerland. <i>Swiss Medical Weekly</i> , 2010, 140, w13059.	1.6	21
126	Association of Noncirrhotic Portal Hypertension in HIV-Infected Persons and Antiretroviral Therapy with Didanosine: A Nested Case-Control Study. <i>Clinical Infectious Diseases</i> , 2009, 49, 626-635.	5.8	117

#	ARTICLE	IF	CITATIONS
127	Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.	3.5	377
128	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	5.8	43
129	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
130	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet, The</i> , 2009, 373, 1352-1363.	13.7	676
131	African descent is associated with slower CD4 cell count decline in treatment-naïve patients of the Swiss HIV Cohort Study. <i>Aids</i> , 2009, 23, 1269-1276.	2.2	28
132	Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 457-463.	2.1	49
133	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.	2.5	18
134	HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. <i>Aids</i> , 2008, 22, 469-479.	2.2	59
135	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1685-1694.	4.0	95
136	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	5.8	35
137	Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1451-1461.	3.0	46
138	Correlation between case mix index and antibiotic use in hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 837-842.	3.0	66
139	Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344.	4.0	145
140	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008, 22, 767-775.	2.2	48
141	Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. <i>Aids</i> , 2008, 22, 2135-2141.	2.2	145
142	Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. <i>PLoS Medicine</i> , 2008, 5, e203.	8.4	1,398
143	Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared. <i>PLoS Medicine</i> , 2008, 5, e148.	8.4	113
144	Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 111-119.	5.8	233

#	ARTICLE	IF	CITATIONS
145	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , 2007, 21, 2223-2229.	2.2	117
146	A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. <i>International Journal of Epidemiology</i> , 2007, 36, 1309-1318.	1.9	22
147	Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment_{title}>A Comparison of Different Regimen Types</sub>. <i>Archives of Internal Medicine</i> , 2007, 167, 1782.	3.8	116
148	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875.	2.2	38
149	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007, 21, 1185-1197.	2.2	264
150	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. <i>Science</i> , 2007, 317, 944-947.	12.6	1,136
151	Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. <i>PLoS ONE</i> , 2007, 2, e173.	2.5	31
152	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , 2006, 20, 1141-1150.	2.2	39
153	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006, 20, 889-894.	2.2	52
154	Factors Associated with the Development of Opportunistic Infections in HIV-1-Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 633-641.	4.0	70
155	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.	3.8	1,004
156	A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-14.	1.0	4
157	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-314.	1.0	10
158	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , 2006, 11, 567-574.	1.0	38
159	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006, 11, 131-142.	1.0	35
160	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005, 19, 1987-1994.	2.2	29
161	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2005, 165, 416.	3.8	124
162	Modeling the Influence ofAPOC3, APOE,andTNFPolymorphisms on the Risk of Antiretroviral Therapy-Associated Lipid Disorders. <i>Journal of Infectious Diseases</i> , 2005, 191, 1419-1426.	4.0	105

#	ARTICLE	IF	CITATIONS
163	Risk Factors for and Outcome of Hyperlactatemia in HIV-Infected Persons: Is There a Need for Routine Lactate Monitoring?. <i>Clinical Infectious Diseases</i> , 2005, 41, 721-728.	5.8	36
164	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÅL in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372.	5.8	285
165	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601.	2.2	472
166	Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. <i>Lancet, The</i> , 2005, 366, 378-384.	13.7	526
167	Influence of Hepatitis C Virus Infection on HIV Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.	4.0	362
168	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , 2005, 10, 791-802.	1.0	55
169	Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, 1178-1185.	5.8	186
170	Antiretroviral Treatment and Osteonecrosis in Patients of the Swiss HIV Cohort Study: A Nested Case-Control Study. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 909-915.	1.1	28
171	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
172	Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. <i>Aids</i> , 2004, 18, 1795-1804.	2.2	26
173	Causes of death in HIV infection. <i>Aids</i> , 2004, 18, 2333-2337.	2.2	34
174	Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. <i>Aids</i> , 2004, 18, 2213-2215.	2.2	14
175	HIV cohort collaborations: proposal for harmonization of data exchange. <i>Antiviral Therapy</i> , 2004, 9, 631-3.	1.0	16
176	Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial. <i>Antiviral Therapy</i> , 2004, 9, 85-95.	1.0	61
177	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.	1.0	11
178	HIV Cohort Collaborations: Proposal for Harmonization of Data Exchange. <i>Antiviral Therapy</i> , 2004, 9, 631-633.	1.0	33
179	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: EuroSIDA Study. <i>Antiviral Therapy</i> , 2004, 9, 787-800.	1.0	7
180	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet, The</i> , 2003, 362, 877-878.	13.7	101

#	ARTICLE	IF	CITATIONS
181	CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years<subtitle>The Swiss HIV Cohort Study</subtitle>. Archives of Internal Medicine, 2003, 163, 2187.	3.8	344
182	HIV-1 p24 Antigen Is a Significant Inverse Correlate of CD4 T-Cell Change in Patients With Suppressed Viremia Under Long-Term Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 292-299.	2.1	41
183	Virological rebound after suppression on highly active antiretroviral therapy. Aids, 2003, 17, 1741-1751.	2.2	99
184	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. Aids, 2003, 17, 2237-2244.	2.2	76
185	Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy, 2003, 8, 443-54.	1.0	8
186	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. Antiviral Therapy, 2003, 8, 127-136.	1.0	24
187	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. Antiviral Therapy, 2003, 8, 443-454.	1.0	23
188	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virusâ€“Infected Patients with Very Low CD4 Cell Counts. Journal of Infectious Diseases, 2002, 186, 189-197.	4.0	52
189	Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a caseâ€“control study from the Swiss HIV Cohort. Aids, 2002, 16, 381-385.	2.2	31
190	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. Journal of Infectious Diseases, 2002, 185, 178-187.	4.0	116
191	A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2002, 185, 1251-1260.	4.0	132
192	Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. Annals of Internal Medicine, 2002, 137, 239.	3.9	122
193	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 Å— 106/l. Aids, 2002, 16, 1371-1381.	2.2	105
194	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. Aids, 2002, 16, 747-755.	2.2	40
195	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.	13.7	1,415
196	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. Aids, 2002, 16, 1967-1969.	2.2	107
197	HIV-1 progression in hepatitis-C-infected drug users. Lancet, The, 2001, 357, 1363.	13.7	2
198	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, The, 2001, 358, 1322-1327.	13.7	317

#	ARTICLE	IF	CITATIONS
199	Importance of Mental Health Assessment in HIV-Infected Outpatients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 240-249.	2.1	44
200	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395.	2.2	61
201	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study. <i>Aids</i> , 2001, 15, 1793-1800.	2.2	39
202	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 397-404.	2.1	12
203	Discontinuation of Secondary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 168-174.	27.0	155
204	Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. <i>Aids</i> , 2000, 14, 2145-2151.	2.2	30
205	Discontinuing or withholding primary prophylaxis against <i>Mycobacterium avium</i> in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , 2000, 14, 1409-1412.	2.2	28
206	Human Immunodeficiency Virus Type 1 p24 Concentration Measured by Boosted ELISA of Heat-Denatured Plasma Correlates with Decline in CD4 Cells, Progression to AIDS, and Survival: Comparison with Viral RNA Measurement. <i>Journal of Infectious Diseases</i> , 2000, 181, 1280-1287.	4.0	73
207	Intestinal Infection Due to Enteraggregative <i>Escherichia coli</i> among Human Immunodeficiency Virus-Infected Persons. <i>Journal of Infectious Diseases</i> , 2000, 182, 1540-1544.	4.0	40
208	Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. <i>Aids</i> , 1999, 13, 943-950.	2.2	335
209	Randomized, Placebo-Controlled Trial of Chinese Herb Therapy for HIV-1-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 22, 56.	0.3	31
210	AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 2220.	7.4	416
211	Incidence and Predictors of Virologic Failure of Antiretroviral Triple-Drug Therapy in a Community-Based Cohort. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1631-1638.	1.1	79
212	Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. <i>BMJ: British Medical Journal</i> , 1999, 319, 23-24.	2.3	208
213	Sex differences in HIV-1 viral load and progression to AIDS. <i>Lancet, The</i> , 1999, 353, 589.	13.7	60
214	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. <i>Lancet, The</i> , 1999, 353, 863-868.	13.7	894
215	Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. <i>Lancet, The</i> , 1999, 353, 1293-1298.	13.7	206
216	Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. <i>Aids</i> , 1999, 13, 2281-2288.	2.2	22

#	ARTICLE	IF	CITATIONS
217	Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. <i>Aids</i> , 1999, 13, 1587.	2.2	24
218	Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. <i>Aids</i> , 1998, 12, 2253-2260.	2.2	36
219	Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 153-160.	0.3	58
220	The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics. <i>International Journal of Public Health</i> , 1994, 39, 387-394.	2.6	138
221	Survival in HIV infection: do sex and category of transmission matter?. <i>Aids</i> , 1994, 8, 1307-1313.	2.2	49